389 related articles for article (PubMed ID: 12566304)
1. Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.
Rice PL; Washington M; Schleman S; Beard KS; Driggers LJ; Ahnen DJ
Cancer Res; 2003 Feb; 63(3):616-20. PubMed ID: 12566304
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
Rice PL; Goldberg RJ; Ray EC; Driggers LJ; Ahnen DJ
Cancer Res; 2001 Feb; 61(4):1541-7. PubMed ID: 11245463
[TBL] [Abstract][Full Text] [Related]
3. Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways.
Rice PL; Peters SL; Beard KS; Ahnen DJ
Mol Cancer Ther; 2006 Mar; 5(3):746-54. PubMed ID: 16546990
[TBL] [Abstract][Full Text] [Related]
4. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
Rice PL; Beard KS; Driggers LJ; Ahnen DJ
Cancer Res; 2004 Nov; 64(22):8148-51. PubMed ID: 15548677
[TBL] [Abstract][Full Text] [Related]
6. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
7. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
9. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
Tong Z; Singh G; Rainbow AJ
Cancer Res; 2002 Oct; 62(19):5528-35. PubMed ID: 12359764
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
Hayakawa J; Ohmichi M; Kurachi H; Kanda Y; Hisamoto K; Nishio Y; Adachi K; Tasaka K; Kanzaki T; Murata Y
Cancer Res; 2000 Nov; 60(21):5988-94. PubMed ID: 11085518
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of early growth response gene 1 (EGR-1) via ERK1/2 signals attenuates sulindac sulfide-mediated cytotoxicity in the human intestinal epithelial cells.
Moon Y; Yang H; Kim YB
Toxicol Appl Pharmacol; 2007 Sep; 223(2):155-63. PubMed ID: 17599376
[TBL] [Abstract][Full Text] [Related]
13. 3-OH flavone inhibition of epidermal growth factor-induced proliferaton through blocking prostaglandin E2 production.
Shen SC; Ko CH; Hsu KC; Chen YC
Int J Cancer; 2004 Feb; 108(4):502-10. PubMed ID: 14696113
[TBL] [Abstract][Full Text] [Related]
14. Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.
Huang Y; He Q; Hillman MJ; Rong R; Sheikh MS
Cancer Res; 2001 Sep; 61(18):6918-24. PubMed ID: 11559570
[TBL] [Abstract][Full Text] [Related]
15. Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells.
Grant ER; Errico MA; Emanuel SL; Benjamin D; McMillian MK; Wadsworth SA; Zivin RA; Zhong Z
Biochem Pharmacol; 2001 Aug; 62(3):283-96. PubMed ID: 11434901
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibitors of MEK1/ERK44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells.
Sun Y; Sinicrope FA
Mol Cancer Ther; 2005 Jan; 4(1):51-9. PubMed ID: 15657353
[TBL] [Abstract][Full Text] [Related]
17. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells.
Murakami-Mori K; Mori S; Bonavida B; Nakamura S
J Immunol; 1999 Mar; 162(6):3672-9. PubMed ID: 10092829
[TBL] [Abstract][Full Text] [Related]
18. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
Lee SY; Shin SJ; Kim HS
Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
[TBL] [Abstract][Full Text] [Related]
19. P2Y(2) nucleotide receptor signaling in human monocytic cells: activation, desensitization and coupling to mitogen-activated protein kinases.
Santiago-Pérez LI; Flores RV; Santos-Berríos C; Chorna NE; Krugh B; Garrad RC; Erb L; Weisman GA; González FA
J Cell Physiol; 2001 May; 187(2):196-208. PubMed ID: 11267999
[TBL] [Abstract][Full Text] [Related]
20. CX-659S, a diaminouracil derivative, indirectly inhibits the function of Langerhans cells by blocking the MEK1/2-Erk1/2 pathway in keratinocytes.
Uchi H; Koga T; Urabe K; Moroi Y; Furue M
J Invest Dermatol; 2003 Jun; 120(6):983-9. PubMed ID: 12787125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
